{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:55:19Z","timestamp":1780480519498,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Infarct size is a major predictor of subsequent cardiovascular events following ST-segment elevation myocardial infarction (STEMI) and is frequently used in clinical trials focused on cardioprotection. Approximately assessed through serial blood sampling, it can be accurately measured by imaging techniques, e.g. cardiac magnetic resonance imaging, which is the actual gold standard for infarct size determination but with limited availability in daily practice. We developed a mathematical biomarker kinetic model based on pharmacokinetic compartment models to easily and accurately estimate infarct size using individual data from five clinical trials evaluating the impact of conditioning therapies in STEMI between 2005 and 2013. Serial blood sampling was available in all studies with data regarding creatine kinase (CK), CK specific of cardiomyocytes (CK-MB) and cardiac troponin I. Our model allowed an accurate estimation of biomarker release as a surrogate marker of infarct size and a powerful assessment of conditioning treatments. This biomarker kinetic modelling approach identified CK-MB as the most accurate biomarker in determining infarct size and supports the development of limited sampling strategies that estimate total biomarker amount released with a lower number of samples. It will certainly be a useful add-on to future studies in the field of STEMI and cardioprotection.<\/jats:p>","DOI":"10.1038\/s41598-017-11352-4","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T14:12:59Z","timestamp":1504188779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Revisiting myocardial necrosis biomarkers: assessment of the effect of conditioning therapies on infarct size by kinetic modelling"],"prefix":"10.1038","volume":"7","author":[{"given":"David","family":"Ternant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Ivanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Prunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Mewton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Bejan-Angoulvant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-1356","authenticated-orcid":false,"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ovize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0788-8092","authenticated-orcid":false,"given":"Denis","family":"Angoulvant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,6]]},"reference":[{"key":"11352_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/01.CIR.79.2.441","volume":"79","author":"E Braunwald","year":"1989","unstructured":"Braunwald, E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation. \n                           79, 441\u2013444 (1989).","journal-title":"Circulation."},{"key":"11352_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/01.CIR.59.1.113","volume":"59","author":"PL Thompson","year":"1979","unstructured":"Thompson, P. L., Fletcher, E. E. & Katavatis, V. Enzymatic indices of myocardial necrosis: influence on short- and long-term prognosis after myocardial infarction. Circulation. \n                           59, 113\u2013119 (1979).","journal-title":"Circulation."},{"key":"11352_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-204","volume":"12","author":"S Desch","year":"2011","unstructured":"Desch, S. et al. Cardiac magnetic resonance imaging parameters as surrogate endpoints in clinical trials of acute myocardial infarction. Trials \n                           12, 204, doi:10.1186\/1745-6215-12-204 (2011).","journal-title":"Trials"},{"key":"11352_CR4","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.ehj.2004.06.040","volume":"25","author":"DJ Pennell","year":"2004","unstructured":"Pennell, D. J. et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J \n                           25, 1940\u20131965, doi:10.1016\/j.ehj.2004.06.040 (2004).","journal-title":"Eur Heart J"},{"key":"11352_CR5","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742cf6","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara, P. T. et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation \n                           127, e362\u2013425, doi:10.1161\/CIR.0b013e3182742cf6 (2013).","journal-title":"Circulation"},{"key":"11352_CR6","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1093\/eurheartj\/ehs184","volume":"33","author":"K Thygesen","year":"2012","unstructured":"Thygesen, K. et al. Third universal definition of myocardial infarction. Eur Heart J \n                           33, 2551\u20132567, doi:10.1093\/eurheartj\/ehs184 (2012).","journal-title":"Eur Heart J"},{"key":"11352_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/cvr\/cvt004","volume":"98","author":"DJ Hausenloy","year":"2013","unstructured":"Hausenloy, D. J. et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res \n                           98, 7\u201327, doi:10.1093\/cvr\/cvt004 (2013).","journal-title":"Cardiovasc Res"},{"key":"11352_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/cvr\/cvx049","volume":"113","author":"DJ Hausenloy","year":"2017","unstructured":"Hausenloy, D. J. et al. Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res \n                           113, 564\u2013585, doi:10.1093\/cvr\/cvx049 (2017).","journal-title":"Cardiovasc Res"},{"key":"11352_CR9","doi-asserted-by":"publisher","first-page":"015","DOI":"10.1007\/s00395-015-0472-y","volume":"110","author":"S Le Page","year":"2015","unstructured":"Le Page, S., Bejan-Angoulvant, T., Angoulvant, D. & Prunier, F. Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials. Basic Res Cardiol \n                           110, 015\u20130467 (2015).","journal-title":"Basic Res Cardiol"},{"key":"11352_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.acvd.2014.08.004","volume":"108","author":"C Touboul","year":"2015","unstructured":"Touboul, C. et al. Ischaemic postconditioning reduces infarct size: systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis \n                           108, 39\u201349 (2015).","journal-title":"Arch Cardiovasc Dis"},{"key":"11352_CR11","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1172\/JCI109004","volume":"61","author":"SF Vatner","year":"1978","unstructured":"Vatner, S. F., Baig, H., Manders, W. T. & Maroko, P. R. Effects of coronary artery reperfusion on myocardial infarct size calculated from creatine kinase. J Clin Invest. \n                           61, 1048\u20131056 (1978).","journal-title":"J Clin Invest."},{"key":"11352_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jacc.2004.06.071","volume":"44","author":"RJ Gibbons","year":"2004","unstructured":"Gibbons, R. J., Valeti, U. S., Araoz, P. A. & Jaffe, A. S. The quantification of infarct size. J Am Coll Cardiol. \n                           44, 1533\u20131542 (2004).","journal-title":"J Am Coll Cardiol."},{"key":"11352_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000173283","volume":"68","author":"R Nordlander","year":"1981","unstructured":"Nordlander, R., Nyquist, O. & Sylven, C. Estimation of infarct size by creatine kinase. A comparison between maximal value, planimetry and computer calculation. Cardiology \n                           68, 201\u2013205 (1981).","journal-title":"Cardiology"},{"key":"11352_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/01.CIR.52.5.743","volume":"52","author":"R Roberts","year":"1975","unstructured":"Roberts, R., Henry, P. D. & Sobel, B. E. An improved basis for enzymatic estimation of infarct size. Circulation. \n                           52, 743\u2013754 (1975).","journal-title":"Circulation."},{"key":"11352_CR15","doi-asserted-by":"publisher","unstructured":"You, B. et al. Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clin Biochem. 41, 785\u2013795, doi:710.1016\/j.clinbiochem.2008.1004.1001, Epub 2008 Apr 1011 (2008).","DOI":"10.1016\/j.clinbiochem.2008.1004.1001"},{"key":"11352_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.urology.2010.02.049","volume":"76","author":"B You","year":"2010","unstructured":"You, B. et al. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor. Urology \n                           76, 423\u2013429 (2010).","journal-title":"Urology"},{"key":"11352_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0614-3","volume":"16","author":"A Ercole","year":"2016","unstructured":"Ercole, A., Thelin, E. P., Holst, A., Bellander, B. M. & Nelson, D. W. Kinetic modelling of serum S100b after traumatic brain injury. BMC Neurol \n                           16, 93, doi:10.1186\/s12883-016-0614-3 (2016).","journal-title":"BMC Neurol"},{"key":"11352_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/2048872616649757","author":"J Nunez","year":"2016","unstructured":"Nunez, J. et al. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. Eur Heart J Acute Cardiovasc Care. doi:10.1177\/2048872616649757 (2016).","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"11352_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/2048872615585518","volume":"5","author":"G Laugaudin","year":"2016","unstructured":"Laugaudin, G. et al. Kinetics of high-sensitivity cardiac troponin T and I differ in patients with ST-segment elevation myocardial infarction treated by primary coronary intervention. Eur Heart J Acute Cardiovasc Care \n                           5, 354\u2013363, doi:10.1177\/2048872615585518 (2016).","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"11352_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.amjcard.2009.10.044","volume":"105","author":"T Senoo","year":"2010","unstructured":"Senoo, T. et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol \n                           105, 624\u2013628, doi:10.1016\/j.amjcard.2009.10.044 (2010).","journal-title":"Am J Cardiol"},{"key":"11352_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.acvd.2014.05.008","volume":"107","author":"F Ivanes","year":"2014","unstructured":"Ivanes, F. et al. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty. Arch Cardiovasc Dis \n                           107, 424\u2013432, doi:10.1016\/j.acvd.2014.05.008 (2014).","journal-title":"Arch Cardiovasc Dis"},{"key":"11352_CR22","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.jacc.2012.03.026","volume":"59","author":"F Thuny","year":"2012","unstructured":"Thuny, F. et al. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol \n                           59, 2175\u20132181, doi:10.1016\/j.jacc.2012.03.026 (2012).","journal-title":"J Am Coll Cardiol"},{"key":"11352_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002708","volume":"4","author":"H Engblom","year":"2016","unstructured":"Engblom, H. et al. Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint. J Am Heart Assoc \n                           4, e002708, doi:10.1161\/JAHA.115.002708 (2016).","journal-title":"J Am Heart Assoc"},{"key":"11352_CR24","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1056\/NEJM199712043372302","volume":"337","author":"CW Hamm","year":"1997","unstructured":"Hamm, C. W. et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med \n                           337, 1648\u20131653, doi:10.1056\/NEJM199712043372302 (1997).","journal-title":"N Engl J Med"},{"key":"11352_CR25","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJM199610313351801","volume":"335","author":"EM Ohman","year":"1996","unstructured":"Ohman, E. M. et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med \n                           335, 1333\u20131341, doi:10.1056\/NEJM199610313351801 (1996).","journal-title":"N Engl J Med"},{"key":"11352_CR26","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/eurheartj\/ehs311","volume":"33","author":"FM Costa","year":"2012","unstructured":"Costa, F. M. et al. Impact of ESC\/ACCF\/AHA\/WHF universal definition of myocardial infarction on mortality at 10 years. Eur Heart J \n                           33, 2544\u20132550, doi:10.1093\/eurheartj\/ehs311 (2012).","journal-title":"Eur Heart J"},{"key":"11352_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/clc.21980","volume":"35","author":"CT Chin","year":"2012","unstructured":"Chin, C. T. et al. Comparison of the prognostic value of peak creatine kinase-MB and troponin levels among patients with acute myocardial infarction: a report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-get with the guidelines. Clin Cardiol \n                           35, 424\u2013429, doi:10.1002\/clc.21980 (2012).","journal-title":"Clin Cardiol"},{"key":"11352_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jcin.2008.04.010","volume":"1","author":"S Chia","year":"2008","unstructured":"Chia, S. et al. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv \n                           1, 415\u2013423, doi:10.1016\/j.jcin.2008.04.010 (2008).","journal-title":"JACC Cardiovasc Interv"},{"key":"11352_CR29","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1136\/heartjnl-2013-303975","volume":"99","author":"SJ Reinstadler","year":"2013","unstructured":"Reinstadler, S. J. et al. Association of copeptin with myocardial infarct size and myocardial function after ST segment elevation myocardial infarction. Heart \n                           99, 1525\u20131529 (2013).","journal-title":"Heart"},{"key":"11352_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/jama.1973.03220010059017","volume":"223","author":"E Eyster","year":"1973","unstructured":"Eyster, E. & Bernene, J. Nosocomial anemia. JAMA \n                           223, 73\u201374 (1973).","journal-title":"JAMA"},{"key":"11352_CR31","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1161\/01.CIR.0000162477.70955.5F","volume":"111","author":"MS Sabatine","year":"2005","unstructured":"Sabatine, M. S. et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation \n                           111, 2042\u20132049, doi:10.1161\/01.CIR.0000162477.70955.5F (2005).","journal-title":"Circulation"},{"key":"11352_CR32","doi-asserted-by":"publisher","unstructured":"Salisbury, A. C. et al. Hospital-acquired anemia and in-hospital mortality in patients with acute myocardial infarction. Am Heart J \n                           162, 300\u2013309 e303, doi:10.1016\/j.ahj.2011.05.021 (2011).","DOI":"10.1016\/j.ahj.2011.05.021"},{"key":"11352_CR33","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1161\/CIRCULATIONAHA.105.558122","volume":"112","author":"P Staat","year":"2005","unstructured":"Staat, P. et al. Postconditioning the human heart. Circulation \n                           112, 2143\u20132148, doi:10.1161\/CIRCULATIONAHA.105.558122 (2005).","journal-title":"Circulation"},{"key":"11352_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1161\/CIRCULATIONAHA.107.729780","volume":"117","author":"H Thibault","year":"2008","unstructured":"Thibault, H. et al. Long-term benefit of postconditioning. Circulation \n                           117, 1037\u20131044, doi:10.1161\/CIRCULATIONAHA.107.729780 (2008).","journal-title":"Circulation"},{"key":"11352_CR35","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/01.CIR.46.4.679","volume":"46","author":"BJ Feild","year":"1972","unstructured":"Feild, B. J., Russell, R. O. Jr., Dowling, J. T. & Rackley, C. E. Regional left ventricular performance in the year following myocardial infarction. Circulation. \n                           46, 679\u2013689 (1972).","journal-title":"Circulation."},{"key":"11352_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0002-8703(03)00112-1","volume":"145","author":"AC Lapeyre 3rd","year":"2003","unstructured":"Lapeyre, A. C. 3rd, St Gibson, W., Bashore, T. M. & Gibbons, R. J. Quantitative regional wall motion analysis with early contrast ventriculography for the assessment of myocardium at risk in acute myocardial infarction. Am Heart J. \n                           145, 1051\u20131057 (2003).","journal-title":"Am Heart J."},{"key":"11352_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1161\/01.CIR.60.1.130","volume":"60","author":"M Rigaud","year":"1979","unstructured":"Rigaud, M. et al. Regional left ventricular function assessed by contrast angiography in acute myocardial infarction. Circulation. \n                           60, 130\u2013139 (1979).","journal-title":"Circulation."},{"key":"11352_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/01.CIR.56.2.199","volume":"56","author":"WJ Rogers","year":"1977","unstructured":"Rogers, W. J. et al. Correlation of angiographic estimates of myocardial infarct size and accumulated release of creatine kinase MB isoenzyme in man. Circulation. \n                           56, 199\u2013205 (1977).","journal-title":"Circulation."},{"key":"11352_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1056\/NEJMoa071142","volume":"359","author":"C Piot","year":"2008","unstructured":"Piot, C. et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med \n                           359, 473\u2013481, doi:10.1056\/NEJMoa071142 (2008).","journal-title":"N Engl J Med"},{"key":"11352_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-013-0383-8","volume":"108","author":"N Mewton","year":"2013","unstructured":"Mewton, N. et al. Postconditioning attenuates no-reflow in STEMI patients. Basic Res Cardiol \n                           108, 383, doi:10.1007\/s00395-013-0383-8 (2013).","journal-title":"Basic Res Cardiol"},{"key":"11352_CR41","doi-asserted-by":"publisher","first-page":"013","DOI":"10.1007\/s00395-013-0400-y","volume":"109","author":"F Prunier","year":"2014","unstructured":"Prunier, F. et al. The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. Basic Res Cardiol \n                           109, 013\u20130400 (2014).","journal-title":"Basic Res Cardiol"},{"key":"11352_CR42","volume":"2012","author":"DR Mould","year":"2012","unstructured":"Mould, D. R. & Upton, R. N. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol \n                           2012, 4 (2012).","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"11352_CR43","doi-asserted-by":"crossref","unstructured":"Savic, R. M., Jonker, D. M., Kerbusch, T. & Karlsson, M. O. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 34, 711\u2013726, Epub 2007 Jul 2026 (2007).","DOI":"10.1007\/s10928-007-9066-0"},{"key":"11352_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/00003088-200241010-00006","volume":"41","author":"F Leger","year":"2002","unstructured":"Leger, F. et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet. \n                           41, 71\u201380 (2002).","journal-title":"Clin Pharmacokinet."},{"key":"11352_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2165\/00003088-200544080-00005","volume":"44","author":"A Premaud","year":"2005","unstructured":"Premaud, A. et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet. \n                           44, 837\u2013847 (2005).","journal-title":"Clin Pharmacokinet."},{"key":"11352_CR46","doi-asserted-by":"publisher","unstructured":"Wilkins, J. J. et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother. 52, 2138\u20132148, doi:2110.1128\/AAC.00461-00407, Epub 02008 Apr 00467 (2008).","DOI":"10.1128\/AAC.00461-00407"},{"key":"11352_CR47","volume":"2013","author":"DR Mould","year":"2013","unstructured":"Mould, D. R. & Upton, R. N. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol \n                           2013, 14 (2013).","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11352-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11352-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11352-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:32:45Z","timestamp":1671791565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11352-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["11352"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-11352-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,6]]},"assertion":[{"value":"15 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10709"}}